Induction Study #1 of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

  • STATUS
    Not Recruiting
  • sponsor
    Celgene
Updated on 26 November 2022
corticosteroids
endoscopy
abdominal pain
ileal disease

Summary

This is a Phase 3, randomized, double-blind, placebo-controlled study to evaluate the effect of oral ozanimod as a potential induction treatment for subjects with moderately to severely active Crohn's Disease.

Description

For more information, please visit www.crohnsstudies.com.

Details
Condition Crohn's Disease (Pediatric), Crohn's, Crohn's Disease, Crohns, Gastroenterology
Clinical Study IdentifierTX279196
SponsorCelgene
Last Modified on26 November 2022

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note